Table 1 Candidate drugs for the up-regulation of FGF20.

From: Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats

Candidate

CMap rank

Expression rank

Class

dimethadione

2

0.74

anti-epileptic

atenolol

3

0.71

cardioselective β blocker

propranolol

5

0.69

non-selective β blocker

clonidine

6

0.67

α2 receptor agonist

estriol

9

0.65

estrogen

luteolin

10

0.65

flavonoid

salbutamol

18

0.58

β2 receptor agonist

equilin

19

0.58

horse estrogen

ethaverine

21

0.56

L-type Ca2+ channel blocker

torsemide

28

0.49

diuretic

sitosterol

30

0.45

phytosterol

levonorgestrel

33

0.42

oral contraceptive

triflusal

34

0.42

platelet aggregation inhibitor

trazodone

35

0.40

5HT2A antidepressant and α1 receptor antagonist

betamethasone

38

0.38

steroid

testosterone

42

0.35

primary male sex hormone

  1. The candidate drugs are ranked based on the expression levels across the 1261 drugs in the CMap database. The relative expression rank of FGF20 in the individual CMap expression profiles is shown in the third column. The remaining 26 drugs within the top 42 were dropped from further analysis due to their inability for blood-brain barrier penetration and having anticipated contraindications either when administered chronically or with other medications frequently used by people with Parkinson’s disease (see Supplementary Table S1).
Back to article page